Vaxinano

💥 Big news in the fight against infectious diseases and new pandemics ! 💉🦠 Vaxinano has raised €6 million 💶 in a funding round led by TCD Capital, Captech Santé, Nord France Amorçage (NFA), Wiseed and a group of business angels, with support from BPI France. These funds will help us propel our flagship vaccines and immunotherapies against leishmaniasis, toxoplasmosis, and other infectious diseases into clinical trials 🌍. Thanks to our groundbreaking Stellar-NP technology 🌟, we are developing a new generation of stable, adjuvant-free nasal vaccines and needle free offering long-lasting protection against the most challenging pathogens, while making vaccination easier and more accessible 💪. 🎯 "This funding marks a major milestone for the commercialization of our vaccine platform and for advancing our vaccines into the clinical phase," said Jonathan Stauber, CEO and Didier Betbeder, Founder & CSO of Vaxinano. Thank you to all our investors for their invaluable support! 🙌 visit our website to learn more about our technologies : www.vaxinano.com ---------- Vaxinano a levé 6 millions d’euros 💶 lors d’un tour de table mené par TCD Capital (ex TheClubDeal), CAPTECH Santé, Nord France Amorçage (NFA), WiSEED et un groupe de business angels, avec le soutien de Bpifrance. Ces fonds vont nous permettre de propulser nos vaccins phares et nos immunothérapies contre la leishmaniose, la toxoplasmose et autres maladies infectieuses vers les essais cliniques 🌍. Grâce à notre technologie unique Stellar-NP 🌟, nous développons une nouvelle génération de vaccins à administration nasale, stables, sans adjuvant et sans aiguille pour des réponses durables contre les pathogènes les plus complexes, tout en rendant la vaccination plus simple et accessible 💪. 🎯 "Ce financement marque une étape cruciale pour la commercialisation de notre plateforme vaccinale et le passage de nos vaccins à la phase clinique", ont déclarés Jonathan Stauber, CEO et Didier Betbeder, fondateur et CSO de Vaxinano. Merci à nos nouveaux investisseurs et les anciens toujours fidèles pour leur soutien précieux ! 🙌 Eurasanté, Réseau Entreprendre, SATT Nord, Recherche - Université de Lille #Vaccine #OneHealth #InfectiousDiseases #NasalVaccine #Deeptech #Vaxinano

🌟 𝐍𝐞𝐰 𝐋𝐞𝐚𝐝𝐞𝐫 𝐉𝐨𝐢𝐧𝐬 𝐕𝐚𝐱𝐢𝐧𝐚𝐧𝐨! 🌟 We are thrilled to welcome Dr. Christophe B. as our new Director of Immunology! 🎉 Dr. Barnier-Quer brings over 15 years of outstanding expertise in immunology, vaccinology, and nanodelivery systems, with a proven track record in both human and animal health research and development. He has held key positions at globally renowned organizations such as MERCK Biodevelopment, GALVmed, and the Vaccine Formulation Laboratory. At Vaxinano, Dr. Barnier-Quer will lead our immunology research group, steering innovative projects to create the next generation of vaccines. His focus will be on leveraging nanotechnology and nasal immunization to revolutionize the future of vaccine delivery. 🚀 Join us in welcoming Dr. Barnier-Quer to the team and celebrating this exciting step forward for Vaxinano’s mission to transform immunization science! #TeamVaxinano #Immunology #Vaccinology #Nanotechnology #NasalVaccines #Innovation #Healthcare

📢 𝐖𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠 𝐃𝐫. 𝐄𝐦𝐢𝐥𝐢𝐨 𝐀. 𝐄𝐦𝐢𝐧𝐢 𝐭𝐨 𝐎𝐮𝐫 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐁𝐨𝐚𝐫𝐝   We are thrilled to announce that Dr. Emilio Emini, has joined our Scientific Advisory Board. Dr. Emini is an internationally recognized leader in biopharmaceutical and vaccine development, bringing over four decades of transformative contributions to global health.   Highlights of Dr. Emini's Remarkable Career:   CEO of the Bill & Melinda Gates Medical Research Institute, driving innovations to tackle some of the world's most pressing infectious diseases. Director of the Tuberculosis & HIV Program at the Bill & Melinda Gates Foundation, addressing global health challenges on a monumental scale. Pioneering Virology & Vaccine Research at Merck, where he led efforts that culminated in the first highly active antiretroviral therapies for HIV/AIDS and the development of multiple licensed vaccines. Senior leadership at Wyeth/Pfizer, advancing a second-generation pneumococcal vaccine that has saved countless lives globally. Advisory roles in critical global health initiatives, including CEPI’s COVID vaccine programs and the U.S. government’s COVID vaccine response. Dr. Emini’s expertise and visionary leadership have shaped the fields of virology, immunology, and vaccine R&D, making an indelible impact on the fight against infectious diseases.   As an elected Fellow of the American Academy of Microbiology, the International Society for Vaccines, and the College of Physicians of Philadelphia, Dr. Emini brings unparalleled experience and insight to our mission.   We are honored to have Dr Emilio Emini guide us in our journey to innovate and advance the future of vaccine science. Welcome to the team, Dr. Emini! Visit Vaxinano Website to learn more : https://lnkd.in/gaCs9ws4 Let’s continue making strides in global health together. 🌍💉

📢 𝐖𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠 𝐃𝐫. 𝐄𝐦𝐢𝐥𝐢𝐨 𝐀. 𝐄𝐦𝐢𝐧𝐢 𝐭𝐨 𝐎𝐮𝐫 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐁𝐨𝐚𝐫𝐝   We are thrilled to announce that Dr. Emilio Emini, has joined our Scientific Advisory Board. Dr. Emini is an internationally recognized leader in biopharmaceutical and vaccine development, bringing over four decades of transformative contributions to global health.   Highlights of Dr. Emini's Remarkable Career:   CEO of the Bill & Melinda Gates Medical Research Institute, driving innovations to tackle some of the world's most pressing infectious diseases. Director of the Tuberculosis & HIV Program at the Bill & Melinda Gates Foundation, addressing global health challenges on a monumental scale. Pioneering Virology & Vaccine Research at Merck, where he led efforts that culminated in the first highly active antiretroviral therapies for HIV/AIDS and the development of multiple licensed vaccines. Senior leadership at Wyeth/Pfizer, advancing a second-generation pneumococcal vaccine that has saved countless lives globally. Advisory roles in critical global health initiatives, including CEPI’s COVID vaccine programs and the U.S. government’s COVID vaccine response. Dr. Emini’s expertise and visionary leadership have shaped the fields of virology, immunology, and vaccine R&D, making an indelible impact on the fight against infectious diseases.   As an elected Fellow of the American Academy of Microbiology, the International Society for Vaccines, and the College of Physicians of Philadelphia, Dr. Emini brings unparalleled experience and insight to our mission.   We are honored to have Dr Emilio Emini guide us in our journey to innovate and advance the future of vaccine science. Welcome to the team, Dr. Emini! Visit Vaxinano Website to learn more : https://lnkd.in/gaCs9ws4 Let’s continue making strides in global health together. 🌍💉

🌍 𝐏𝐮𝐛𝐥𝐢𝐜 𝐇𝐞𝐚𝐥𝐭𝐡 𝐀𝐥𝐞𝐫𝐭: 𝐅𝐢𝐫𝐬𝐭 𝐅𝐚𝐭𝐚𝐥 𝐂𝐚𝐬𝐞 𝐨𝐟 𝐇𝟓𝐍𝟏 𝐁𝐢𝐫𝐝 𝐅𝐥𝐮 𝐢𝐧 𝐋𝐨𝐮𝐢𝐬𝐢𝐚𝐧𝐚 The Louisiana Department of Health has reported the state's first fatal case of H5N1 bird flu in a human. This tragic event underscores the urgent need for innovative solutions to tackle zoonotic diseases—those that can jump from animals to humans—and to prevent future outbreaks. At Vaxinano, we are deeply committed to addressing these challenges. Our cutting-edge Stellar-NP technology focuses on the development of nasal and mucosal vaccines, offering unique advantages in combating zoonotic diseases like avian influenza. These vaccines not only promise enhanced protection but are also tailored for scalable deployment to at-risk populations. This case highlights the importance of cross-sector collaboration, advanced vaccine research, and proactive public health measures to safeguard global health. Link : https://lnkd.in/eYH5zGvF #PublicHealth #Vaxinano #H5N1 #OneHealth #Vaccines #Innovation

🌍 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬: 𝐀 𝐍𝐞𝐰 𝐄𝐫𝐚 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 The recent article by McKinsey & Company, Beyond the Pandemic: The Next Chapter of Innovation in Vaccines, highlights the transformative trends shaping the vaccine landscape. From advanced delivery platforms to next-generation formulations, it’s clear that the vaccine industry is entering an era of unprecedented opportunity and impact. At Vaxinano, we are proud to be at the forefront of this innovation. Our proprietary STELLAR-NP technology is designed to enable nasal and mucosal delivery of vaccines, offering: ✅ Enhanced efficacy through targeted immune responses. ✅ Non-invasive administration, improving accessibility and compliance. ✅ Thermostability of the vaccines. ✅ Broad potential to combat both human and veterinary diseases. As McKinsey emphasizes, the future lies in collaborations that blend cutting-edge science and scalable solutions. Vaxinano is actively seeking partnerships to accelerate the deployment of our platform and bring next-generation vaccines to those who need them most. Let’s shape the next chapter of vaccine innovation together. 🌟 https://lnkd.in/ejknk2tf #Vaccines #Innovation #Biotech #STELLARNP #Vaxinano

🌍 Another Milestone in Wildlife Health! 🐒✨ The Sorocaba Zoo in Brazil has started vaccinating its primates against toxoplasmosis, marking an important step in protecting vulnerable wildlife from this parasitic disease. This initiative showcases the growing importance of innovative veterinary vaccines in ensuring the health of endangered species. At Vaxinano, we are proud to contribute to global efforts in wildlife conservation through our cutting-edge nasal vaccine solutions. It's inspiring to see advancements like this reinforcing the critical role of science in safeguarding biodiversity. Link to the publication : https://lnkd.in/dKziw4ZC Let's continue to work together to protect our planet's incredible wildlife! 💡🌿 #Conservation #WildlifeHealth #Toxoplasmosis #Vaccines #Biodiversity

🎄 Season’s Greetings from Vaxinano! 🎄 As the year comes to a close, we want to take a moment to express our heartfelt gratitude to our partners, collaborators, and supporters. 2024 has been an incredible year filled with milestones, innovations, and partnerships that brought us closer to our vision of transforming vaccine. This festive season, we celebrate not only our achievements but also the shared commitment to advancing health—be it for humans or animals. 🌍🐾 Looking ahead to 2025, we are filled with excitement and determination to continue innovating, growing, and creating a positive impact. Thank you for being a part of this journey! From everyone at Vaxinano, we wish you a joyful holiday season and a New Year filled with health, happiness, and success. ✨ #HappyHolidays #Vaxinano

🌟 𝐍𝐚𝐬𝐚𝐥 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬: 𝐓𝐡𝐞 𝐠𝐚𝐦𝐞 𝐜𝐡𝐚𝐧𝐠𝐞𝐫 𝐨𝐟 𝐢𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧? 🌟 The recent attention on AstraZeneca's FluMist reminds us how nasal vaccines can revolutionize vaccine delivery. By targeting mucosal immunity, they don’t just protect the individual—they could reduce transmission, especially for respiratory illnesses. At Vaxinano, we're proud to be part of this innovation wave with our Stellar-NP platform, advancing nasal vaccines for human and veterinary applications. Nasal delivery is more than convenience; it's about efficacy, accessibility, and scalability. What do you think—are nasal vaccines the game-changer we've been waiting for? Let’s discuss! Link to the publication in comments :-) #Vaccines #Innovation #NasalDelivery #Biotech

🌟 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐥𝐞𝐚𝐝𝐞𝐫𝐬 𝐣𝐨𝐢𝐧 𝐕𝐚𝐱𝐢𝐧𝐚𝐧𝐨 ! 🌟 We are thrilled to announce the appointment of two esteemed leaders to our board: Joachim Hasenmaier, former Board Member at Boehringer Ingelheim, and Kenny Simmen, a biopharmaceutical expert with a distinguished career at Johnson & Johnson. This marks a significant step forward for Vaxinano as we continue to advance our innovative STELLAR-NP platform and redefine the future of nasal and mucosal vaccine delivery. 💡 𝐃𝐫. 𝐉𝐨𝐚𝐜𝐡𝐢𝐦 𝐇𝐚𝐬𝐞𝐧𝐦𝐚𝐢𝐞𝐫 is a senior healthcare executive with over 30 years of experience in mainly animal but also human health, spanning pharmaceuticals, vaccines, and medtech. He excels in transforming businesses, notably turning a marginal animal health unit into a global leader through internal growth and strategic acquisitions. 💡 𝐃𝐫. 𝐊𝐞𝐧𝐧𝐲 𝐒𝐢𝐦𝐦𝐞𝐧 is a recognized leader in biologics and vaccine development, with deep experience in bringing advanced biotechnologies to market. Through his subsequent global role as VP, head of external innovation for Infectious Diseases & Vaccines with Johnson & Johnson Innovation he led the establishment of many international collaborations, license agreements with companies and academic teams in the US, Asia and Europe. Their insights and experience will be invaluable as we accelerate toward clinical trials, forge global partnerships, and expand applications of our technology in both human and animal health. Welcome to the team, Joachim Hasenmaier and Kenny Simmen! Together, we’re one step closer to delivering transformative, accessible vaccines to the world. 🌍 #Vaxinano #Innovation #Vaccines #STELLARNP #Biotech #Healthcare #AnimalHealth